Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15449

IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment

Título : IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment
Autor : Sánchez Vera, Isabel
Escudero Lirola, Esther
Muñoz Morón, Úrsula
Sádaba Argaiz, María Cruz
Materias: BiomarkersDiagnosisPrognosisIgMInterferon-βMultiple sclerosisPhosphatidylcholineTysabri®
Editorial : SAGE Publications
Citación : Sánchez-Vera I, Escudero E, Muñoz Ú, Sádaba MC. IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment. Therapeutic Advances in Neurological Disorders. 2023;16. doi:10.1177/17562864231189919
Resumen : Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous system. It affects young people, and a considerable percentage of patients need the help of a wheelchair in 15 years of evolution. Currently, there is not a specific technique for the diagnosis of MS. The detection of oligoclonal IgG bands (OIgGBs) is the most sensitive assay for it, but it is not standardizable, only reference laboratories develop it, and uses cerebrospinal fluid. To obtain this sample, a lumbar puncture is necessary, an invasive proceeding with important side effects. It is important to develop and implement standard assays to obtain a rapid diagnosis because the earlier the treatment, the better the evolution of the disease. There are numerous modifying disease therapies, which delay the progression of the disease, but they have important side effects, and a considerable percentage of patients give up the treatment. In addition, around 40% of MS patients do not respond to the therapy and the disease progresses. Numerous researches have been focused on the characterization of predictive biomarkers of response to treatment, in order to help physicians to decide when to change to a second-line treatment, and then the best therapeutic option. Here, we review the new biomarkers for the diagnosis and response to treatment in MS. We draw attention in a new assay, the detection of serum IgM to phosphatidylcholine, that showed a similar sensitivity as OIgGBs and predicts the response to disease modifying treatments.
URI : http://hdl.handle.net/10637/15449
Derechos: http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
OpenAccess
ISSN : 1756-2864
Fecha de publicación : 17-ago-2023
Centro : Universidad San Pablo-CEU
Aparece en las colecciones: Medicina





Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.